Table 4.1Results of the base-case analysis

StrategyT1T2T3Total Expected QALYsTotal Expected CostsICERs (cost per QALY)
3GEM+DOCCAPVIN£30,3131.2018£62,300
13DOCCAPVIN£23,0551.0853£23,332
14DOCCAPNo Chemo£18,1180.8737£14,979
9PACCAPNo Chemo£16,6920.7785£7,796
12PACNo Chemo£13,4410.3615

GEM = gemcitabine; DOC = docetaxel; CAP = capecitabine; VIN = vinorelbine; PAC = paclitaxel

From: 4, Systemic disease-modifying therapy

Cover of Advanced Breast Cancer
Advanced Breast Cancer: Diagnosis and Treatment.
NICE Clinical Guidelines, No. 81.
National Collaborating Centre for Cancer (UK).
Copyright © 2009, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.